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Background: Candida albicans is a common cause of a variety of superficial and invasive disseminated infections
the majority of which are associated with biofilm growth on implanted devices. The aim of the study is to evaluate
the activity of amphotericin B and voriconazole against the biofilm and the biofilm-dispersed cells of Candida
albicans using a newly developed in vitro pharmacokinetic model which simulates the clinical situation when the
antifungal agents are administered intermittently.
Methods: RPMI medium containing 1–5 X 106 CFU/ml of C. albicans was continuously delivered to the device at
30 ml/h for 2 hours. The planktonic cells were removed and biofilms on the catheter were kept under continuous
flow of RPMI medium at 10 ml/h. Five doses of amphotericin B or voriconazole were delivered to 2, 5 and 10
day-old biofilms at initial concentrations (2 and 3 μg/ml respectively) that were exponentially diluted. Dispersed
cells in effluents from the device were counted and the adherent cells on the catheter were evaluated after 48 h of
the last dose.
Results: The minimum inhibitory concentration of voriconazole and amphotericin B against the tested isolate was
0.0325 and 0.25 μg/ml respectively. Amphotericin B significantly reduced the dispersion of C. albicans cells from the
biofilm. The log10 reduction in the dispersed cells was 2.54-3.54, 2.30-3.55, and 1.94-2.50 following addition of 5
doses of amphotericin B to 2-, 5- and 10-day old biofilms respectively. The number of the viable cells within the
biofilm was reduced by 18 (±7.63), 5 and 4% following addition of the 5 doses of amphotericin B to the biofilms
respectively. Voriconazole showed no significant effect on the viability of C. albicans within the biofilm.
Conclusion: Both antifungal agents failed to eradicate C. albicans biofilm or stop cell dispersion from them and the
resistance progressed with maturation of the biofilm. These findings go along with the need for removal of devices
in spite of antifungal therapy in patients with device-related infection. This is the first study which investigates the
effects of antifungal agents on the biofilm and biofilm-dispersion of C. albicans in an in vitro pharmacokinetic
biofilm model.
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Fungal infections are most commonly caused by Can-
dida spp., particularly C. albicans, Candida tropicalis
and Candida parapsilosis [1,2]. These yeasts are oppor-
tunistic pathogens that are capable of causing a variety
of superficial and invasive disseminated infections [3].
Their emergence as important nosocomial pathogens is
associated with modern medical procedures, such as the
use of immunosuppressive and cytotoxic drugs, broad
spectrum antibiotics, and the use of central venous
catheters as well as implanted devices of various kinds
[4,5]. Data from the US National Health Care Safety
Network (NHSN) rank these Candida species as the
fourth most common cause of bloodstream infection,
behind coagulase-negative staphylococci, Staphylococ-
cus aureus and enterococci [6] with mortality rate ap-
proaching 40% [7].
Among Candida species, C. albicans is the most com-
mon cause of invasive infections. It is the leading cause of
disseminated fungal infection in neonates, immunocom-
promised hosts, diabetics, and postoperative patients [8].
Candida species resistant to antifungal agents have
been reported worldwide [9]. Biofilm formation by Can-
dida species and resistance to antifungal agents are im-
portant factor in their contribution to human disease.
Recent evidence suggests that the majority of disease
produced by C. albicans is associated with biofilm growth
[10]. C. albicans is the fourth and third leading cause of
hospital-acquired bloodstream and urinary tract infec-
tions, respectively [11]. Up to 70–80% of Candida blood-
stream infections are associated with central venous
catheters, and the majority of Candida urinary tract in-
fections are associated with indwelling urinary catheters
[12]. Candida biofilms were found to be resistant to
clinically important antifungal agents including ampho-
tericin B and azoles [13,14].
In vivo intermittent administration of antibiotics usu-
ally results in incremental decline in the antibiotic levels
in serum and tissues with the microorganisms being
exposed to both supra- and sub- minimum inhibitory
concentrations (MICs) during the dosing interval.
Therefore, in vitro experiments that subject microorgan-
isms to constant levels of antibiotics do not reflect the
true in vivo interaction [15]. Several in vitro kinetic
models have been constructed to simulate the serum
antibiotic concentration-time curve obtained in humans
[15]. These models are mainly used to study the micro-
organisms in the planktonic phase while few of them
were developed to study bacterial biofilms [16,17].
The aim of the present study is to investigate the anti-
fungal activity of amphotericin B and voriconazole against
the biofilm and the biofilm-dispersed cells of C. albicans
in an in vitro model that mimics the in vivo interactions
when the drugs are administered intermittently. For thispurpose, a new pharmacokinetic biofilm model, which
uses a novel biofilm device, was developed. This is the first
study which investigates the effects of antifungal agents
on biofilm and the dispersed biofilm cells of C. albicans in
a pharmacokinetic model.
Materials and methods
Unless otherwise indicated, all chemicals (analytical
grade) were purchased from Sigma-Aldrich, Saint Louis,
Missouri, USA.
Antifungal
Amphotericin B (Amp-B) was purchase from Sigma-
Aldrich, Saint Louis, Missouri, USA. Voriconazole
(VCZ) was kindly provided by Pfizer, United Kingdom.
Microorganism
A clinical isolate of C. albicans (CA04), isolated from
blood of a patient with central venous catheter, was used
in this study. The isolate was identified to species level
by using API 20 C AUX for yeast, Bio Merieux, Vitek
Inc., Hazelwood, Missouri, USA.
In vitro susceptibility of C. albicans to Amp-B and VCZ
The susceptibility of the isolate to Amp-B and VCZ was
determined by broth microdilution method described by
the Clinical and Laboratory Standards Institute (CLSI)
[18]. After determining the MIC, the minimum fungi-
cidal concentration (MFC) of each drug required to kill
99% of the yeast cells was determined by spreading of
10 μl portions from each well with no growth on
Sabouraud Dextrose Agar plates. Following incubation
for 24 hours, the plates were observed for growth and
the MFCs were calculated.
In vitro biofilm device
A novel in vitro biofilm device was developed (Figure 1).
The device comprises a tubular body defining a test
chamber. The size of the test chamber is of 10 cm height
and 0.80 cm diameter with a volume of 5 ml. The body
has upper and lower ends provided with closures. Each
of the ends has one port which can be used as an outlet
or inlet based on the study conditions. The body has a
built in side port and all the three ports can be con-
nected to a tubing system or blocked by the removable
closures. The ports in the upper and lower ends of the
device are designed to mount the tested materials (cath-
eters or tubes). The design allows the fluid to be
pumped through the inner lumen of the implant tube
before filling the inner chamber to allow biofilm forma-
tion on the inner and outer surfaces of the catheters.
The various parts of the device may be fabricated from
stainless steel, Pyrex glass or other materials which do
not affect the formation of the biofilm.
Figure 1 A novel in vitro biofilm device integrated in a pharmacokinetic biofilm model system. The device was configured to simulate the
in vivo condition in which the biofilms of C. albican on IV vascular catheter are under continuously perfusion with fresh medium and exposed to
exponentially decreasing concentrations of antifungal agents.
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low laminar flow system with very low shear stress on
the inner and outer catheter surfaces.
Pharmacokinetic biofilm model in a dynamic cell flow
system
The device was configured to simulate the in vivo condi-
tion in which microorganisms are exposed to supra and
sub MIC of the antifungal agents following intermittent
administration of the drugs as in clinical practice
(Figure 1). The system is a typical dynamic cell flow
system in which antifungal agent can be delivered to the
biofilm in sequence by two intra venous (IV) infusion
pumps. The first pump delivers fresh medium at a spe-
cific flow rate to a second container which contains the
antimicrobial agent at a concentration equivalent to its
Cmax (The peak concentration of a drug observed after
its administration in the human body). A second pump
is used to deliver the fresh medium with antimicrobial
agent to the biofilm. Perfusing biofilms with media via
the dilution vessel into which drugs were added allows
biofilm cells to be exposed to exponentially decreasing
concentrations of antifungal agent. Once the biofilms
reached a steady state, the drugs were added directly to
the dilution vessel. The dilution rate of the drug was
similar to their in vivo half-lives and the volume of the
medium in the dilution vessel was calculated from the
equation t1/2 = 0.6931 V/r, where r is the rate of flow of
medium and V is the volume of medium, as the reaction
follows first-order decay kinetics [16]. The half-lives of
the antifungal agents used in these experiments are 24
and 6.5 hours for Amp-B and VCZ respectively [19,20].The flow rate was kept at 10 ml/h throughout all
experiments.
Evaluation of the antifungal activity of Amp-B and VCZ
on mature biofilms and biofilm-dispersed cells of C.
albicans
The biofilm device was used to study the effects of
Amp-B and VCZ on mature biofilms and the biofilm
dispersed cells of C. albicans on vascular catheter (Per-
ipheral venous catheter BD Angiocath, reference number
382259, Becton, Dickinson and Company, USA). Briefly,
24 hours old culture of C. albicans on Sabouraud Dex-
trose Agar was used to inoculate RPMI medium adjusted
to pH 7 by using MOPS (3-(N-morpholino) propansul-
fonic acid). The initial inoculum size was standardized
in the medium to give 1–5 X 106 CFU/ml. The suspen-
sion was then continuously delivered to the device at
30 ml/h for 2 hours. The planktonic (free) cells were
removed by delivering sterile RPMI at the same rate for
another 2 hours. The biofilms on the catheter were kept
under continuous flow of fresh RPMI medium at 10 ml/
h. Amp-B and VCZ were tested against 2, 5 and 10 day-
old biofilms at initial concentrations equal to their Cmax,
2 and 3 μg/ml respectively [18,19]. The rate of delivery
of the drugs and the plain medium was kept at 10 ml/h
and by this way the drugs delivered to the biofilms were
exponentially diluted at a rate that follows first order
kinetics. Four other doses of Amp-B and VCZ were
added to the dilution vessel every 24 and 12 hours re-
spectively. One milliliter portions of the effluent samples
from the device were taken for cell count (dispersed
cells) 24 and 12 hours after addition of each dose of the
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the catheters were aseptically removed from the device
and cut to 1 cm segments. The part of the catheter
which is proximal to the medium entry, about 1 cm
length between Port 1 and 2, was excluded in further
assaying of the biofilm because the medium is allowed
to flow out the device from port#2 before reaching this
part. All other segments were transferred to test tubes
containing 1 ml saline and the adherent cells were
dislodged by sonication in aquasonic device, vortexed
for 1 minute and counted by trypan blue exclusion and
viable count on Sabouraud Dextrose Agar. Drug-free
experiments were used as controls where the effect of
the antifungal agents on the dispersed cells from and the
viable cells within the biofilms were calculated compared
to the positive controls.Scanning electron microscopy
The Scanning Electron Microscope was used to visualize
the biofilm of C. albicans on the catheters after 24 hours
perfusion with the medium. Catheters, on which the
biofilm was formed as described above, were aseptically
cut to 1 cm segments and prepared for Scanning Elec-
tron Microscope examination as previously described
[21]. Briefly, they were fixed in glutaraldehyde in 0.1 M
cacodylate buffer containing 0.15 ruthenium red for 3 h at
4°C. The segments were then rinsed in fresh 0.1 M caco-
dylate buffer for 10 min (repeated three times) and post-
fixed in 1.5% osmium tetroxide for 1 hour. They were
dehydrated in a series of aqueous ethanol solutions
(30–100%) and dried by a critical point dryer (Auto-
samdri) with CO2. The specimens were mounted on
aluminium stubs with silver paste, allowed to dry for
3 hours and then coated with gold/palladium using a
cool-sputter coater E5100 II (Polaron Instruments).
The segments were then examined in the electron
microscope (S-500; Hitachi) at 20 kV.
One milliliter portions containing dispersed cells were
collected from the 2-day old biofilms before adding the
antifungal agents (control), and before adding the third
dose of Amp-B or VCZ. The samples were centrifuged
at 10,000 rpm for 30 minutes and the sediments were
collected, washed with normal saline, fixed in glutaralde-
hyde in 0.1 M cacodylate buffer containing 0.15 ruthe-
nium red for 3 hours at 4°C and examined as previously
described.Statistical analysis
Each experiment was performed in quadruplicate and
the mean and the Standard Deviation (S.D.) were calcu-
lated. One-way analysis of variance (ANOVA) was used
to determine the differences between various treatments.
Tukey’s pair comparison test was used at the chosenlevel of probability (P < 0.05) to determine significance
difference between means.Results
In vitro susceptibility of C. albicans to Amp-B and VCZ
The MIC of VCZ (0.0325 μg/ml) was eight fold less than
that of Amp-B (0.25 μg/ml). The MFC of Amp-B was
0.50 μg/ml while VCZ (a fungistatic agent) was not able
to kill the fungus at the maximum tested concentration
(64 μg/ml).Evaluation of the antifungal activity of Amp-B and VCZ
on biofilm-dispersed cells of C. albicans
The dispersed cells from the biofilm were quantified be-
fore adding each dose of the antifungal agents. Amp-B
significantly (p < 0.05) reduced the number of dispersed
cells of C. albicans from the biofilm (Figures 2 and 3). It
was noted that with exponentially decreasing exposure
of the biofilms to Amp-B or VCZ, the older the biofilm,
the less was the reduction in the number of dispersed
cells from it. The maximum log10 reduction in the num-
ber of eluted cells from the biofilms occurred after the
second dose of the antifungal agents, and the reduction
values not significantly changed after exposure to the
remaining three doses (p > 0.05). When 5 doses of Amp-
B were added to 2-day old biofilm, the dispersed cells
were reduced by 2.54-3.54 logs. The log10 reduction was
2.30-3.55, and 1.94-2.50 following addition of Amp-B to
5- and 10-day old biofilms. On the other hand, VCZ did
not show such activity against the dispersed cells. The
log10 reduction was 0.43-1.22, 0.50-1.11 and 0.16-1.02
when 5 doses of VCZ were added to 2-, 5- and 10-day
old biofilms respectively.Evaluation of the antifungal activity of Amp-B and VCZ
on the mature biofilms of C. albicans
The antifungal agents were tested against 2-, 5-, and 10-
day old biofilms of C. albicans in the pharmacokinetic
biofilm model (Figure 4). Adherent cells were evaluated
by viable count of the released cells following sonication
of the biofilms. The biofilms of C. albicans were resist-
ant to the antifungal drugs. Amp-B was more active
against the 2-day old biofilms compared to the effect on
5- and 10-day old biofilms. Following addition of 5 doses
to 2-day old biofilms, Amp-B reduced the number of the
viable cells within the biofilm by 18% (±7.63) compared
to untreated biofilms (drug-free controls), while the re-
duction was 5 and 4% following addition of the antifun-
gal agent to 5- and 10-day old biofilms. VCZ, on the
other hand, showed no significant effect on the viability
of C. albicans within the tested biofilms after addition of
5 doses of the drug compared to drug-free controls.
Figure 2 Activity of amphotericin B on the dispersion of cells from mature biofilms of C. ablicans following addition of 5 doses of the
antifungal agent. The doses were added at 24 hours intervals and the effluent samples, 1 milliliter portions, were collected after 24 hours of
addition of each dose.
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albicans and the effect of Amp-B and VCZ on biofilm
dispersion using Scanning Electron Microscopy
The scanning electron micrograph (SEM) of 24 hour old
biofilm shows the typical pattern of C. albicans cells in
the biofilm which consists of yeast form cells (blasto-
spores) and long tubular hyphal cells (Figure 5A). OnFigure 3 Activity of voriconazole on the dispersion of cells from matu
antifungal agent. The doses were added at 12 hours intervals. The effluen
of each dose.the other hand, the SEM shows that the dispersed C.
albicans cells from the biofilms were in yeast form only
(Figure 5B, C and D). The SEM was used, semi quantita-
tively, to compare the number of dispersed cells of C.
albicans following treatment of the biofilms with 2 doses
of Amp-B or VCZ compared to drug-free sample. The
reduction in the number of dispersed cells was obviousre biofilms of C. ablicans following addition of 5 doses of the
t samples, 1 milliliter portions, were collected after 12 hours of addition
Figure 4 The antifungal activity of amphotericin B and voriconazole against mature biofilms of C. albians on IV vascular catheter
following addition of 5 doses of the antifungal agents. The viable cells within the biofilm were determined after 48 hours of the last dose
and calculated as colony forming unit (CFU) per 1 cm of the catheter segment.
Figure 5 Scanning Electron Micrograph (SEM) shows. (A) the architecture of 24 hours old biofilm of C. albicans on IV vascular catheter
following continuous perfusion of the biofilm with fresh medium. (B) The dispersed cells collected from 1 milliliter effluent sample from the
biofilm of C. albicans on vascular catheter following 2 day of continuous perfusion by fresh medium. (C) The dispersed cells collected from 1
milliliter effluent sample from 2-day old biofilm of C. albicans on vascular catheter following addition of 2 doses of amphotericin B at 24 hours
intervals. (D) The dispersed cells collected from 1 milliliter effluent sample from 2-day old biofilm of C. albicans on vascular catheter following
addition of 2 doses of voriconazole at 12 hours intervals. Note that in the biofilm, the cells exist in the yeast and the long tubular hyphal forms
while the dispersed cells exist as yeast cell form only.
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Amp-B compared to VCZ.
Discussion
Candida infection associated with biofilm formation is a
serious nosocomial problem. The resistance of C. albicans
biofilms enables the organism to escape the immune
response as well as the antifungal drug activity [22].
Biofilm-associated microbial infection in humans is
widespread and increasing, and occurs largely as a con-
sequence of the increase in the use of indwelling medical
devices, such as intravenous and urinary catheters, pace-
makers and prosthetic joints [23]. Recent evidence sug-
gests that the majority of disease produced by C.
albicans is associated with biofilm formation [10].
In this study, a newly developed in vitro pharmacoki-
netic biofilm model (that simulates the in vivo conditions)
in which microorganisms are exposed to supra and sub
MIC of the drugs was used. The pharmacokinetic model
simulates the serum antibiotic concentration-time curve
obtained during intermittent administration of the anti-
fungal agents in clinical practice. These experimental con-
ditions can be achieved by a dilution method in which the
reactions follow first order kinetics [16,17,24]. The novel
biofilm device was constructed to fit the conditions of the
experiment. Its design makes it easy to contain a full
length catheter in the main chamber instead of using
segments or piece of plastics as in other available devices.
The device can also be adjusted to different configurations
to fit the experimental conditions, static or dynamic sys-
tem, required to simulate and study interaction between
microbial biofilms and antimicrobial agents.
Intravenous catheter was selected as a model of the
indwelling device to study antifungal activity of the two
drugs on the biofilms of C. albicans. Catheter-related in-
fections are the major cause of morbidity and mortality
among hospitalized patients, and the biofilms on cathe-
ters are associated with 90% of these infections [11].
Catheter-associated Candida biofilms can lead to candi-
demia with an approximate incidence of one case per
100 hospital admissions [25]. Biofilm-associated Candida
infections cause mortality rates as high as 30%, with
annual cost of antifungal therapy estimated at US$2.6
billion in the United Sates [26,27].
For this study, we chose to compare Amp-B, a conven-
tional broad spectrum antifungal agent, with VCZ, a rep-
resentative of the triazole class, with the aim of evaluating
our in vitro model. Both drugs are not first line therapy in
invasive Candida infection. Treatment of candidemia with
fluconazole, first line therapy, and Amp-B have demon-
strated comparable results [28,29]. VCZ, on the other
hand, has shown equivalent or even better activity against
Candida species compared to fluconazole [30-32]. The
antifungal activity of Amp-B and VCZ was evaluated bymeasuring their effect on the dispersed cells from the bio-
film and the viability of the cells within the biofilm follow-
ing the exposure to 5 doses of the antifungal agents. It was
noted that with incrementally decreasing exposure of the
biofilms to the drugs, there was declining reduction in the
number of dispersed cells from older biofilms (Figures 2
and 3). The maximum log10 reduction in the number of
eluted cells from the biofilms occurred after the second
dose of the antifungal agents, and changed insignificantly
upon exposure to the remaining three doses (p > 0.05). In
a pharmacokinetic study conducted by Gander et al. [17],
linezolid at exponentially decreasing concentrations was
tested against the dispersed cells from staphylococcal bio-
films. They found that the maximum log10 reduction in
the dispersed cells was observed after the first dose. When
a biofilm is at steady state, cells are shed from it at a con-
stant rate, which could be considered as the normal rate.
The biofilms in this model were exposed first to concen-
trations above the MICs and then to subinhibitory con-
centrations of the drugs. Subinhibitory concentrations of
antimicrobial agents often influence the growth rate of the
microorganisms [33].
The number of cells dispersed from a biofilm de-
creases when the biofilm is exposed to an inhibitory
concentration of a drug, and increases on removal of the
drug, eventually returning to the original steady state
[16]. Dispersed cells of C. albicans from biofilm to circu-
lation may cause biofilm-associated candidemia. These
dispersed cells have been found to have a different pat-
tern of antimicrobial susceptibility from the same cells
that exist in the biofilm or planktonic phase of growth
[34]. In our model, Amp-B significantly (p < 0.5) reduced
the number of dispersed cells from the biofilm com-
pared to drug-free control but could not completely stop
the dispersion process. VCZ, on the other hand, was less
active in reducing dispersed cells.
Amp-B significantly (p < 0.05) reduced the number of
the viable cells within the 2-day old biofilms compared
to control samples (Figure 4), This effect was not ob-
served with the 5- and 10-day old biofilms. VCZ showed
no effect on the viability of C. albicans within all tested
biofilms. It has been reported that the progression of
drug resistance within Candida biofilms is associated
with a parallel increase in the maturation process [35].
Biofilm cells typically have very slow growth rates and
are surviving under nutrient limitation compared to
planktonic cells grown in batch cultures in vitro [16].
Other mechanisms have been postulated to explain re-
calcitrance of the biofilm to antimicrobial agents includ-
ing contact-dependent gene expression, interaction with
the extracellular polymeric matrix, and poor penetration
through the biofilm mass [14,21].
The scanning electron micrograph (Figure 5A) shows
that the biofilm of C. albicans consists of blastospores
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biofilms grown in vitro often have a foundation of yeast
cells from which a hyphal layer originates [1]. In general,
the Candidal biofilm consists of a dense network of yeast
cells, pseudohyphae, and hyphae, which are very difficult
to eradicate by antifungal agents [21].
It would be expected that the older the biofilm, the
more complex and dense the network of the yeast cells,
which in turn would make the biofilm more recalcitrant
by acting as a barrier for the antifungal agents. Unlike
the cells in the biofilm, dispersed cells of C. albicans
appeared in yeast form (Figure 5B, C and D). It has been
reported that C. albicans biofilm dispersion is dependent
on growing conditions, and that the dispersed cells are
mostly in the yeast form [36]. The SEM supports our
finding that Amp-B was capable of reducing the disper-
sion of the C. albicans from the biofilms but not to the
extent of stopping it.Conclusion
One clinical isolate of C. albicans was used to validate
the biofilm device and to study the antimicrobial activity
of the selected antifungal agents against the biofilm and
the cells dispersed from it. The antifungal activity of both
antifungal agents was inefficient against C. albicans cells
that grew in or dispersed from the biofilms in the con-
structed model. The model mimics the conditions in vivo
when the biofilm is formed, dispersed and treated follow-
ing exposure to the antifungal agents at concentrations
that decrease exponentially similar to the intermittent
administration in clinical practice. Amp-B, a conventional
broad spectrum antifungal agent, and VCZ, a model of tri-
azole antifungals, failed to stop the dispersion of C. abli-
cans cells or to eradicate the biofilm of the yeast cells. Our
results support the clinical finding that the formation of
biofilms inside an implant device leads to failure of the
device and acts as a source of refractory infections. It is
difficult to treat the implant-associated infection not
only due to failure of the antimicrobial agents to kill
the cells within the biofilm but also to stop dispersion
of cells that leads to dissemination which necessitates
the removal of the device.
This is the first study which investigates the effects of
antifungal agents on the biofilm and biofilm-dispersion
of C. albicans in an in vitro pharmacokinetic biofilm
model.
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